Bristol-Myers Squibb Co. (BMY)

58.90
1.10 1.90
NYSE : Health Technology
Prev Close 57.83
Open 57.99
Day Low/High 57.66 / 59.27
52 Wk Low/High 49.96 / 70.05
Volume 6.55M
Avg Volume 5.64M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 94.01B
EPS 0.60
P/E Ratio 240.04
Div & Yield 1.60 (2.76%)

Latest News

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

NEW YORK and HOLON, Israel, Oct. 11, 2018 /PRNewswire/ --  Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of...

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb And Compugen Announce Clinical Collaboration To Evaluate Therapeutic Regimen In Advanced Solid Tumors

Bristol-Myers Squibb Company (NYSE: BMY) and Compugen (NASDAQ: CGEN) today announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen's COM701, an investigational anti-PVRIG antibody, in...

Biotech and Broadway Come Together to Fight Cancer

Biotech and Broadway Come Together to Fight Cancer

Cancer affects all of us. But the Damon Runyon Cancer Research Foundation has invested $355 million (and counting) in research to fight it. We spent time with its CEO to hear about her journey and how immunotherapies are taking the lead.

Consider These Diagnostic Testing Firms

Consider These Diagnostic Testing Firms

Diagnostic firms can have an advantage of recurring revenue streams.

European Medicines Agency Validates Bristol-Myers Squibb's Application For Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone In Patients With Multiple Myeloma

European Medicines Agency Validates Bristol-Myers Squibb's Application For Empliciti (elotuzumab) Plus Pomalidomide And Low-Dose Dexamethasone In Patients With Multiple Myeloma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated the Company's type II variation application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone (EPd) for...

Bristol-Myers Squibb Announces Dividend

Bristol-Myers Squibb Announces Dividend

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty cents ($0.

Bristol-Myers Squibb's Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance In Patients With Moderate To Severe Plaque Psoriasis In Phase 2 Trial

Bristol-Myers Squibb's Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance In Patients With Moderate To Severe Plaque Psoriasis In Phase 2 Trial

Bristol-Myers Squibb Company (NYSE:BMY) today announced results from a Phase 2 study of BMS-986165, an investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis.

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb To Take Part In Morgan Stanley Global Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Morgan Stanley 2018 Global Health Care Conference on Thursday, September 13, 2018, in New York.

Bristol-Myers Squibb To Announce Results For Third Quarter 2018 On October 25

Bristol-Myers Squibb To Announce Results For Third Quarter 2018 On October 25

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter of 2018 on Thursday, October 25, 2018.

We Are Riding For Patients

We Are Riding For Patients

Today, for the fifth year in a row, Bristol-Myers Squibb Company (NYSE:BMY) is launching Coast 2 Coast 4 Cancer, a nearly month-long cross-country bike ride to raise money for cancer research.

(Photo: Business Wire)

(Photo: Business Wire)

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Christopher Boerner, Ph.

Here's Why You Should Invest in Immunotherapy Companies

Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.

Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying

Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying

Let's take a fresh look at the charts.

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

U.S. Food And Drug Administration Approves Opdivo® (nivolumab) As The First New Medication In Nearly 20 Years For Certain Patients With Previously Treated Small Cell Lung Cancer

U.S. Food And Drug Administration Approves Opdivo® (nivolumab) As The First New Medication In Nearly 20 Years For Certain Patients With Previously Treated Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) received approval from the U.

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) For The Adjuvant Treatment Of Adult Patients With Melanoma With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection

European Commission Approves Bristol-Myers Squibb's Opdivo (nivolumab) For The Adjuvant Treatment Of Adult Patients With Melanoma With Involvement Of Lymph Nodes Or Metastatic Disease Who Have Undergone Complete Resection

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone...

I See More Volatility Ahead

Although it would not surprise me if we see a rally attempt on Tuesday.

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Reports Second Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2018, which were highlighted by strong sales for Eliquis (apixaban) and Opdivo (nivolumab), and important regulatory progress in the company's Immuno-Oncology...

Bristol-Myers Squibb And Tsinghua University Announce Collaboration To Accelerate Early Research Into Potential Therapies For Autoimmune Diseases And Cancer

Bristol-Myers Squibb And Tsinghua University Announce Collaboration To Accelerate Early Research Into Potential Therapies For Autoimmune Diseases And Cancer

Bristol-Myers Squibb Company (NYSE: BMY) and Tsinghua University, have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers.

Bristol-Myers Squibb Announces Departure Of Chief Commercial Officer

Bristol-Myers Squibb Announces Departure Of Chief Commercial Officer

Bristol-Myers Squibb Company (NYSE:BMY) today announced that Murdo Gordon, executive vice president and chief commercial officer, is leaving the company, effective August 3, 2018, to pursue another opportunity.

Bristol-Myers Squibb And Gritstone Oncology Announce Clinical Research Collaboration To Evaluate Novel Immunotherapy Approach In Advanced Solid Tumors

Bristol-Myers Squibb And Gritstone Oncology Announce Clinical Research Collaboration To Evaluate Novel Immunotherapy Approach In Advanced Solid Tumors

Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone's personalized neoantigen immunotherapy, GRANITE-001,...

3 Pharma Stocks Goldman Sachs Sees as Buys

3 Pharma Stocks Goldman Sachs Sees as Buys

The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.

Bristol-Myers Squibb's Opdivo® (nivolumab) Low-Dose Yervoy® (ipilimumab) Is The First Immuno-Oncology Combination Approved For MSI-H/dMMR MCRC Patients Who Progressed Following Treatment With A Fluoropyrimidine, Oxaliplatin And...

Bristol-Myers Squibb's Opdivo® (nivolumab) Low-Dose Yervoy® (ipilimumab) Is The First Immuno-Oncology Combination Approved For MSI-H/dMMR MCRC Patients Who Progressed Following Treatment With A Fluoropyrimidine, Oxaliplatin And...

Bristol-Myers Squibb Company (NYSE: BMY) today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) received approval from the U.

Only Immuno-Oncology Combination Therapy Approved By Health Canada As First-Line Treatment For Advanced Or Metastatic Renal Cell Carcinoma

Only Immuno-Oncology Combination Therapy Approved By Health Canada As First-Line Treatment For Advanced Or Metastatic Renal Cell Carcinoma

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) combination is the first and only treatment to show significantly superior overall survival versus current standard of care in intermediate- and poor-risk advanced or metastatic renal cell carcinoma 1 MONTREAL,...

European Commission Approves Expanded Indication For Sprycel (dasatinib) To Include Treatment Of Children With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase

European Commission Approves Expanded Indication For Sprycel (dasatinib) To Include Treatment Of Children With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia In Chronic Phase

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Commission (EC) has expanded the indication for Sprycel (dasatinib) to include the treatment of children and adolescents aged 1 year to 18 years with Philadelphia...

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo (nivolumab) For The Adjuvant Treatment Of Adult Patients With Melanoma

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo (nivolumab) For The Adjuvant Treatment Of Adult Patients With Melanoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended expanded approval of the current indications for Opdivo (nivolumab) to include the...

TheStreet Quant Rating: C+ (Hold)